Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd.
Explore linked clinical trials.8 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Active, not recruiting | Phase 3 | 2026-09-29 | NCT06608927 | |
| Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities | RET-altered Non Small Cell Lung Cancer; RET-altered Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-08-19 | NCT04683250 | |
| A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome | Hemic and Lymphatic Diseases, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Recruiting | Phase 1 | 2026-08-10 | NCT04608110 | |
| AB122 Platform Study | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, alveolar soft part sarcoma, biliary tract cancer, biliary tract disorder, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, esophageal cancer, esophageal disorder, gastric cancer, gastric neoplasm, head and neck cancer, intestinal disorder, lung disorder, lung neoplasm, myomatous neoplasm, neoplasm, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma, rectal disorder, respiratory system disorder, respiratory tract neoplasm, sarcoma, stomach disorder | Recruiting | Phase 1 | 2026-08-05 | NCT04999761 | |
| Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer | Biliary Tract Neoplasms, Bone Diseases, Developmental, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Craniofacial Abnormalities, Digestive System Diseases, Digestive System Neoplasms, Limb Deformities, Congenital, Musculoskeletal Abnormalities, Neoplasms by Site, autosomal dominant Parkinson disease 4, biliary tract cancer, biliary tract disorder, bone disorder, craniosynostosis, dysostosis, musculoskeletal system disorder, neoplasm, syndactyly, synostosis | Recruiting | Phase 3 | 2026-07-17 | NCT07710885 | |
| A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC | non-small cell lung carcinoma | Active, not recruiting | Phase 2 | 2026-06-22 | NCT05773092 | |
| Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colon adenocarcinoma, colonic disorder, colonic neoplasm, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 1 | 2026-05-11 | NCT04920032 | |
| A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, gastrointestinal stromal tumor, neoplasm | Active, not recruiting | Phase 1 | 2026-01-20 | NCT05245968 |